• Aoxing Pharmaceutical Co. Inc., of Jersey City, N.J., appointed Guoan Zhang acting chief financial officer and Guirong Zhou vice president of R&D.

• Arena Pharmaceuticals Inc., of San Diego, named Craig Audet senior vice president, operations and head of global regulatory affairs.

• Dynavax Technologies Corp., of Berkeley, Calif., appointed David Happel vice president of global sales and marketing.

• Endocyte Inc., of West Lafayette, Ind., added Peter Meldrum to its board.

• KaloBios Pharmaceuticals Inc., of South San Francisco, named Jeffrey Cooper chief financial officer.

• Knome Inc., of Cambridge, Mass., added Heidi Rehm to its scientific advisory board.

• Merrimack Pharmaceuticals Inc., of Cambridge, Mass., named William McClements senior vice president of corporate operations.

• NovImmune SA, of Plan-Les-Ouates, Switzerland, added Michael Steinmetz to its board and appointed David Slack head of corporate and business development.

• Oncos Therapeutics Ltd., of Helsinki, Finland, added Kapil Dhingra, Lee Helman, Kevin Harrington, Eva Galanis, Luca Gianni and Elke Jager to its clinical advisory board (CAB). Mikael von Euler was named chairman of the CAB.

• Onyx Pharmaceuticals Inc., of South San Francisco, named John Osborn senior vice president, global corporate affairs.

• Organovo Holdings Inc., of San Diego, added James Glover to its board.

• Photocure ASA, of Oslo, Norway, appointed Erik Dahl chief financial officer, effective Aug. 15.

• Savient Pharmaceuticals Inc., of East Brunswick, N.J., appointed Louis Ferrari president and CEO.

• Xenetic Biosciences plc, of London, added Subash Kapre and Thomas Ulich to its scientific advisory board.